drugset
drugset / Trial / NCT00949767

Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

NCT00949767 ↗

Phase 1 Completed 64 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics of ascending single doses of BMS-866949 in healthy subjects.

Timeline

Start
2009-07
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-866949 Unknown 0.5 mg Oral
Subject BMS-866949 Unknown 2.5 mg Oral
Subject BMS-866949 Unknown 10 mg Oral
Subject BMS-866949 Unknown 25 mg Oral
Subject BMS-866949 Unknown 50 mg Oral
Subject BMS-866949 Unknown 100 mg Oral
Subject BMS-866949 Unknown 150 mg Oral

Indications

depressive disorder